What is Ischemic Heart Disease?
Ischemic Heart Disease (IHD) is a heart problem that happens when the heart doesn't get enough blood during periods of excitement or physical activity. It occurs because the arteries that supply blood to the heart become blocked due to plaque buildup. This lack of blood supply can cause chest pain and discomfort known as angina pectoris.
When the arteries remain blocked for extended periods, the heart tissues suffer from a lack of blood supply, leading to their necrosis and causing a condition known as myocardial infarction. The progression of this condition is usually gradual and exhibits minimal symptoms. Common indications include chest pain and difficulty in breathing. Depending on the patient's condition, a variety of medications such as nitrates, statins, beta-blockers, and antiplatelet drugs are available, alongside treatment options like angioplasty and coronary artery bypass graft.
Market Outlook for Ischemic Heart Disease
The projected expansion of the ischemic heart disease market is anticipated to propel its growth, primarily due to the increasing majority of IHDs worldwide. Factors such as a rising mortality rate, advancements in healthcare systems, population growth, and a surge in heart problems caused by obesity and sedentary lifestyles are expected to drive the demand for ischemic heart disease treatments from 2021 to 2028.
However, certain obstacles may hinder market growth. The high cost associated with treatment and the ongoing uncertainty surrounding reimbursement policies is expected to impede the expansion of the ischemic heart disease market. Furthermore, the mounting concerns regarding potential side effects on the body pose a significant challenge to the market.
Factors Driving the Growth of the Ischemic Heart Disease Market
IHD ranks among the top ten leading causes of mortality worldwide, according to the World Health Organization (WHO). The high prevalence of chronic conditions like diabetes, hypertension, and elevated cholesterol levels further increases the risk of cardiovascular diseases, including IHD. Moreover, increased funding for developing advanced IHD drugs contributes to market expansion.
Conclusion
The Ischemic Heart Disease (IHD) market is expected to witness significant growth due to the rising prevalence of IHD worldwide, coupled with factors such as a high mortality rate, advancements in healthcare systems, and increased heart problems associated with obesity and sedentary lifestyles. The market is driven by the growing population affected by IHD and increased funding for advanced drug development.
Author's Detail
Surabhi Bhaiyya, LinkedIn
Surabhi Bhaiyya is an experienced market researcher focused on the Pharma & Healthcare industry. With over 7+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions.
Author's Detail:
Surabhi Bhaiyya /
LinkedIn
Senior Research Analyst at Cognitive Market Research
Surabhi Bhaiyya is an experienced market researcher focused on the Pharma & Healthcare industry. With over 7+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
